Studies on ultrafiltration of antihemophilic factor

Ultrafiltration as an alternative approach to reprecipitation was studied in the production of an intermediate-purity antihemophilic factor concentrate suitable for clinical use. Almost complete recoveries of factor-VIII-related activities have been demonstrated across the processing step resulting in increased net yield of the product. Several important processing parameters are discussed. The product thus prepared is stable and has improved VIII:C/mg fibrinogen ratio.